PHAZAR

Trial description
A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase MyeloproliferatIve neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.
Contact name
Dr Anna Godfrey
Trial start date
Tuesday, June 12, 2018
Trial end date
Tuesday, December 31, 2019
Trial tumour type
Haematological
Show on Radiotherapy
No